APLS:NGS-Apellis Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 18.05

Change

-0.17 (-0.93)%

Market Cap

USD 1.01B

Volume

0.42M

Yahoo Analyst Target

USD 39.50 (118.84%)

STA Analyst Target

USD 29.67 (64.36%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-09-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+0.86 (+0.43%)

USD 131.53B
GILD Gilead Sciences Inc.

+0.21 (+0.29%)

USD 95.77B
BIIB Biogen Inc.

+2.02 (+0.60%)

USD 68.27B
CELG Celgene Corporation

-0.23 (-0.26%)

USD 61.46B
SHPG Shire plc

+0.43 (+0.24%)

USD 46.69B
VRTX Vertex Pharmaceuticals Incorpo..

-0.52 (-0.29%)

USD 45.13B
REGN Regeneron Pharmaceuticals Inc.

-4.63 (-1.19%)

USD 41.46B
ALXN Alexion Pharmaceuticals Inc.

+1.15 (+0.95%)

USD 27.18B
BMRN BioMarin Pharmaceutical Inc.

+0.21 (+0.21%)

USD 17.72B
GRFS Grifols S.A.

+0.05 (+0.24%)

USD 14.41B

ETFs Containing APLS

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.82% 43% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.82% 43% F 22% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 1.01B 77% C+ 68% D+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -12.89 80% B- 83% B
Price/Book Ratio 7.81 24% F 15% F
Price / Cash Flow Ratio -3.16 71% C- 86% B
Price/Free Cash Flow Ratio -13.78 72% C- 82% B-
Management Effectiveness  
Return on Equity -65.34% 43% F 16% F
Return on Invested Capital -56.38% 50% F 18% F
Return on Assets -53.79% 43% F 13% F
Debt to Equity Ratio 12.75% 56% F 74% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

APLS:NGS-Apellis Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 18.05

Change

-0.17 (-0.93)%

Market Cap

USD 1.01B

Volume

0.42M

Yahoo Analyst Target

USD 39.50 (118.84%)

STA Analyst Target

USD 29.67 (64.36%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-09-19